Rhonda L. Jordan
Known title: DirectorCIK: 0001359770
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target. Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.
Transaction History
| ESAB | ▲ Buy | Option Exercise | 1,000 | $33K | 8/7/2026 | View on chart |
| ESAB | ▼ Sell | Open Market | 1,000 | $95K | 8/7/2026 | View on chart |
| INGR | ▲ Buy | Grant | 1,797 | $193K | 5/20/2026 | View on chart |
| INGR | ▲ Buy | Grant | 380 | $43K | 3/31/2026 | View on chart |
| INGR | ▲ Buy | Grant | 371 | $40K | 12/5/2025 | View on chart |
| INGR | ▲ Buy | Grant | 321 | $40K | 9/30/2025 | View on chart |
| ESAB | ▲ Buy | Option Exercise | 4,067 | $134K | 8/13/2025 | View on chart |
| ESAB | ▼ Sell | Open Market | 4,067 | $460K | 8/13/2025 | View on chart |
| INGR | ▲ Buy | Grant | 291 | $40K | 6/30/2025 | View on chart |
| ESAB | ▲ Buy | Option Exercise | 1,500 | $50K | 6/11/2025 | View on chart |
| ESAB | ▼ Sell | Open Market | 1,500 | $190K | 6/11/2025 | View on chart |
| INGR | ▲ Buy | Grant | 302 | $40K | 3/31/2025 | View on chart |
| INGR | ▲ Buy | Grant | 275 | $40K | 12/12/2024 | View on chart |
| ESAB | ▲ Buy | Option Exercise | 4,254 | $172K | 10/30/2024 | View on chart |
| ESAB | ▼ Sell | Open Market | 4,254 | $532K | 10/30/2024 | View on chart |
| INGR | ▲ Buy | Grant | 295 | $40K | 9/30/2024 | View on chart |
| INGR | ▲ Buy | Grant | 347 | $40K | 6/28/2024 | View on chart |
| INGR | ▲ Buy | Grant | 342 | $40K | 3/29/2024 | View on chart |
| ESAB | ▲ Buy | Option Exercise | 1,700 | $84K | 3/1/2024 | View on chart |
| ESAB | ▼ Sell | Tax Withholding | 857 | $84K | 3/1/2024 | View on chart |
| ESAB | ▼ Sell | Open Market | 843 | $83K | 3/1/2024 | View on chart |
| INGR | ▲ Buy | Grant | 361 | $38K | 12/11/2023 | View on chart |
| ESAB | ▲ Buy | Option Exercise | 1,700 | $84K | 11/2/2023 | View on chart |
| ESAB | ▼ Sell | Tax Withholding | 1,161 | $84K | 11/2/2023 | View on chart |
| ESAB | ▼ Sell | Open Market | 539 | $39K | 11/2/2023 | View on chart |
| INGR | ▲ Buy | Grant | 377 | $37K | 9/29/2023 | View on chart |
| INGR | ▲ Buy | Grant | 354 | $38K | 6/30/2023 | View on chart |
| INGR | ▲ Buy | Grant | 381 | $37K | 3/31/2023 | View on chart |
| ESAB | ▼ Sell | Open Market | 3,810 | $234K | 3/9/2023 | View on chart |
| ESAB | ▲ Buy | Option Exercise | 3,810 | $118K | 3/9/2023 | View on chart |
| INGR | ▲ Buy | Grant | 480 | $39K | 10/3/2022 | View on chart |
| INGR | ▲ Buy | Grant | 451 | $40K | 7/1/2022 | View on chart |
| ESAB | ▲ Buy | Grant | 6,003 | $0 | 4/5/2022 | View on chart |
| ESAB | ▲ Buy | Grant | 266 | $0 | 4/5/2022 | View on chart |
| ESAB | ▲ Buy | Grant | 2,063 | $0 | 4/5/2022 | View on chart |
| INGR | ▲ Buy | Grant | 468 | $40K | 4/1/2022 | View on chart |
| INGR | ▲ Buy | Grant | 417 | $41K | 1/3/2022 | View on chart |
| INGR | ▲ Buy | Grant | 387 | $35K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
ESAB Schedules Q3 2026 Earnings Call Amid Mixed Stock Performance
ESAB has announced the schedule for its third-quarter 2026 earnings release and conference call. This announcement follows a period of mixed price action, with recent reports noting both sharp declines and significant gains in the stock. The company is preparing to share updated financial results as investors monitor its performance against a 52-week range of $64.83 to $137.42.
ESAB Schedules Q3 2026 Earnings Call Amid Mixed Stock Performance. ESAB has announced the schedule for its third-quarter 2026 earnings release and conference call. This announcement follows a period of mixed price action, with recent reports noting both sharp declines and significant gains in the stock. The company is preparing to share updated financial results as investors monitor its performance against a 52-week range of $64.83 to $137.42.